SCHEMBL23726759

SCHEMBL23726759

Cc1cc(Br)cn2c(=O)cc(CCl)nc12

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 2/20 0.41
TDP1 Q9NUW8 1/20 0.41
PABPC1 P11940 2/20 0.39
RXFP1 Q9HBX9 2/20 0.38
ALDH1A1 P00352 2/20 0.38
MAPT P10636 2/20 0.38
SMN1; SMN2 Q16637 3/20 0.37
PKM P14618 1/20 0.37
L3MBTL1 Q9Y468 1/20 0.36
PRNP P04156 3/20 0.36
TRPA1 O75762 1/20 0.36
GALR3 O60755 1/20 0.36
PSD A5PKW4 1/20 0.36
HTR6 P50406 1/20 0.36
ALOX15 P16050 1/20 0.35
NPC1 O15118 1/20 0.34
MAPK1 P28482 1/20 0.34
AHR P35869 1/20 0.34
KCNQ3 O43525 1/20 0.34
KCNQ2 O43526 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22101427 0.87 PABPC1 (0.42) KDM4EPABPC1RXFP1MAPTPKM
SCHEMBL28903269 0.78 RXFP1 (0.42) PABPC1RXFP1L3MBTL1PRNPTRPA1
SCHEMBL22101884 0.73 MAPT (0.37) KDM4ETDP1RXFP1ALDH1A1MAPT
SCHEMBL23726394 0.73 RXFP1 (0.56) KDM4ETDP1RXFP1ALDH1A1MAPT
SCHEMBL11920167 0.72 KDM4E (0.53) KDM4ETDP1RXFP1ALDH1A1MAPT
SCHEMBL23725715 0.71 CD274 (0.43)
SCHEMBL23725717 0.71 CD274 (0.43)
SCHEMBL22101696 0.71 KDM5B (0.39) KDM4ERXFP1ALDH1A1MAPTSMN1; SMN2
SCHEMBL22393919 0.71 KDM5B (0.36) KDM4ETDP1RXFP1ALDH1A1MAPT
SCHEMBL19348539 0.69 KCNQ3 (0.39) KDM4ETDP1ALDH1A1MAPTSMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230143612-A1 SUBSTITUTED 1,1'-BIPHENYL COMPOUNDS AND METHODS USING SAME ARBUTUS BIOPHARMA CORP (US) 2023-05-11 US disclosed
US-20230143612-A1 SUBSTITUTED 1,1'-BIPHENYL COMPOUNDS AND METHODS USING SAME ARBUTUS BIOPHARMA CORP (US) 2023-05-11 US disclosed
US-20230143612-A1 SUBSTITUTED 1,1'-BIPHENYL COMPOUNDS AND METHODS USING SAME ARBUTUS BIOPHARMA CORP (US) 2023-05-11 US disclosed
EP-4100381-A1 SUBSTITUTED 1,1'-BIPHENYL COMPOUNDS AND METHODS USING SAME Arbutus Biopharma Corporation (CA) 2022-12-14 EP disclosed
CN-115413275-A Substituted 1,1 , -biphenyl compounds and methods of use thereof 爱彼特生物制药公司 2022-11-29 CN disclosed
WO-2021158481-A1 SUBSTITUTED 1,1'-BIPHENYL COMPOUNDS AND METHODS USING SAME ARBUTUS BIOPHARMA, INC. (US) 2021-08-12 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230143612-A1 SUBSTITUTED 1,1'-BIPHENYL COMPOUNDS AND METHODS USING SAME HAVCR2, HMBS, VHL KDM4E 224/4885TDP1 1060/4885PABPC1 997/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.